HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a hormone shot help fight advanced breast cancer? new trial begins
Disease control Recruiting nowThis Phase 1 trial is testing ZOLADEX (goserelin), a hormone-blocking implant, in 88 premenopausal women with HR+/HER2- advanced breast cancer. The goal is to see if it can temporarily shut down ovarian function, which may help control the cancer. Participants receive two injecti…
Matched conditions: HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: TerSera Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough breast cancer: drug cocktail trial launches
Disease control Recruiting nowThis study tests whether adding two drugs (entinostat and anlotinib) to a standard hormone therapy (fulvestrant) can shrink tumors or slow cancer growth in people with a common type of advanced breast cancer (HR+/HER2-). About 118 adults whose cancer returned or worsened after pr…
Matched conditions: HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo shows promise in slowing advanced breast cancer
Disease control Recruiting nowThis study tests a new drug called QL1706 in people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if it can slow down the cancer's growth and check for side effects. About 123 women will take part, and the results will be compared to standard care.
Matched conditions: HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Wenjin Yin • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC